ENCELTO™ (revakinagene taroretcel-lwey) / NT-501

About Neurotech Pharmaceuticals

Neurotech Pharmaceuticals is a pioneering biotech company that has successfully developed and commercialized the first-ever therapy for Macular Telangiectasia Type 2 (MacTel), a previously untreatable retinal disease. The company's proprietary Encapsulated Cell Therapy platform enables long-term, localized delivery of therapeutic proteins like Ciliary Neurotrophic Factor (CNTF) to protect photoreceptors. Having secured FDA approval and a permanent J-Code for reimbursement in 2025, Neurotech has transitioned to a commercial-stage company, positioning it to address a significant unmet need in ophthalmology and potentially expand its platform to other chronic eye diseases.

Therapeutic Areas